Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation, Indication, Distribution Channel

List of Tables

[186 Pages Report] The Antacids Market size was estimated at USD 6.85 billion in 2023 and expected to reach USD 7.24 billion in 2024, at a CAGR 5.81% to reach USD 10.18 billion by 2030.

Antacid is a type of medication that is used to neutralize stomach acidity and alleviate symptoms associated with excess gastric acid. These include conditions such as heartburn, indigestion, and stomach upset, providing relief by increasing the pH balance in the stomach. The antacid products are available in various forms, including tablets, liquids, and powders to relieve symptoms associated with gastroesophageal reflux disease (GERD), heartburn, and peptic ulcers. The rising prevalence of GERD, heartburn, and other gastric ailments globally is driving the need for antacid products. Modern dietary habits and lifestyles contribute to increased incidences of acidity and related disorders, further propelling the demand for antacids. Continuous research and development aimed at enhancing product efficacy and reducing side effects positively impact market growth. However, stringent regulations regarding the approval and marketing of antacid products can delay product launches, hampering market growth. The availability of alternative therapies and treatments for acid-related disorders poses a significant challenge for market growth. Moreover, ongoing research into natural and organic ingredients can effectively relieve acidity and related conditions, creating opportunities for market growth. Ongoing innovation in drug delivery technologies to improve the efficacy and duration of action of antacid products, generating growth potential in the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.85 billion
Estimated Year [2024]	USD 7.24 billion
Forecast Year [2030]	USD 10.18 billion
CAGR (%)	5.81%

Regional Insights

In the Americas region, the antacids market is driven by a high prevalence of gastroesophageal reflux disease (GERD) and stress-induced gastritis, amongst other digestive disorders. Consumer preferences lean toward fast-acting, flavored, and chewable forms in major countries such as the United States and Canada. The EMEA region presents a diverse landscape for antacids as the EU countries prioritize medically proven, prescription-based treatments due to stringent regulations. The EMEA market is characterized by a strong presence of global pharmaceutical brands and a growing interest in antacids that offer additional health benefits, such as probiotics. The antacids market in the Middle East and Africa is expanding, driven by lifestyle diseases and an increasing preference for self-medication. Moreover, in the APAC region, the burgeoning middle-class population and increased healthcare spending in China and India are expanding the adoption of antacids in the region. The rising aging population in Japan and a strong focus on preventive healthcare bolster the use of antacids in the APAC region. The domestic antacids market in India is propelled by lifestyle changes, increased fast food consumption, and rising awareness of over-the-counter (OTC) remedies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Antacids Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Growing population suffering from gastroesophageal reflux disease
- Government initiatives and investments for domestic drug manufacturing worldwide

Market Restraints
- Availability of home remedies and other alternatives for acidity-related issues

Market Opportunities
- Development of more instantly effective and long-lasting antacids
- Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs

Market Challenges
- Drug recall and contamination issues associated with the antacids

Market Segmentation Analysis
- Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
- Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
- Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
- Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antacids Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antacids Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time

TUMS partners with DraftKings to introduce an innovative platform, TUMS Prop Bites. This unique initiative creates awareness about making free food predictions by offering a chance to compare their selections with others nationwide. The brand's antacid tablets and chews are crafted to immediately relieve heartburn. These chewable solutions address symptoms such as heartburn, acid indigestion, sour stomach, and discomfort. [Published On: 2024-01-17]

Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio

Dexcel Pharma Ltd. announced its strategic acquisition of eight reputable over-the-counter (OTC) brands to diversify and strengthen its consumer healthcare offerings. The enhanced portfolio features well-known products such as EarCalm Spray, Sominex for sleep assistance, Wind-Eze as an antacid, Bisodol for indigestion relief, Cymex for cold sore treatment, Liberize for erectile dysfunction, Yeast Vite supplements, and MacKenzies Smelling Salts for catarrh and colds. [Published On: 2024-01-11]

Camber Pharmaceuticals Launches Generic Wellbutrin SR

Camber Pharmaceuticals expanded its product line by introducing Famotidine Powder for oral suspension, USP, a treatment developed to address various gastrointestinal conditions. Suitable for adults, this formulation effectively treats active duodenal and gastric ulcers, relieving the symptoms of non-erosive gastroesophageal reflux disease (GERD). [Published On: 2023-11-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antacids Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Acid Neutralizers
  - Aluminum Hydroxide
  - Calcium Carbonate
  - Magnesium Hydroxide
  - Sodium Bicarbonate

H2 Antagonist
Promotility Agents
Proton Pump Inhibitor

Formulation
- Liquid
- Powder
- Tablet

Indication
- Gastroesophageal Reflux Disease
- Indigestion/Dyspepsia
- Peptic Ulcer Disease

Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-4358BACA7E3E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing population suffering from gastroesophageal reflux disease
  - 5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
- 5.1.2. Restraints
  - 5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
- 5.1.3. Opportunities
  - 5.1.3.1. Development of more instantly effective and long-lasting antacids
  - 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
- 5.1.4. Challenges
  - 5.1.4.1. Drug recall and contamination issues associated with the antacids
5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
- 5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
- 5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
- 5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
5.3. Market Trend Analysis
- 5.3.1. Rising prevalence of gastroesophageal reflux disease across the Americas creating need for antacids
- 5.3.2. Government campaigns creating awareness for enhancing digestive health in the Asia-Pacific
- 5.3.3. Presence of well-established pharmaceutical industry and government support for domestic drug manufacturing in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Antacids Market, by Drug Class

6.1. Introduction
6.2. Acid Neutralizers
6.3. H2 Antagonist
6.4. Promotility Agents
6.5. Proton Pump Inhibitor

7. Antacids Market, by Formulation

7.1. Introduction
7.2. Liquid
7.3. Powder
7.4. Tablet

8. Antacids Market, by Indication

8.1. Introduction
8.2. Gastroesophageal Reflux Disease
8.3. Indigestion/Dyspepsia
8.4. Peptic Ulcer Disease

9. Antacids Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy

10. Americas Antacids Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Antacids Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Antacids Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
- 13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
- 13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
- 13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
- 13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
- 13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
- 13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
- 13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
- 13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
- 13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio